GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » Quick Ratio

InnoCare Pharma (HKSE:09969) Quick Ratio : 3.77 (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is InnoCare Pharma Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. InnoCare Pharma's quick ratio for the quarter that ended in Jun. 2024 was 3.77.

InnoCare Pharma has a quick ratio of 3.77. It generally indicates good short-term financial strength.

The historical rank and industry rank for InnoCare Pharma's Quick Ratio or its related term are showing as below:

HKSE:09969' s Quick Ratio Range Over the Past 10 Years
Min: 0.51   Med: 19.46   Max: 68.01
Current: 3.77

During the past 7 years, InnoCare Pharma's highest Quick Ratio was 68.01. The lowest was 0.51. And the median was 19.46.

HKSE:09969's Quick Ratio is ranked better than
53.49% of 1503 companies
in the Biotechnology industry
Industry Median: 3.41 vs HKSE:09969: 3.77

InnoCare Pharma Quick Ratio Historical Data

The historical data trend for InnoCare Pharma's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Quick Ratio Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial 36.68 39.16 19.46 4.45 4.13

InnoCare Pharma Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.36 4.13 4.14 3.77 -

Competitive Comparison of InnoCare Pharma's Quick Ratio

For the Biotechnology subindustry, InnoCare Pharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCare Pharma's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's Quick Ratio distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's Quick Ratio falls into.



InnoCare Pharma Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

InnoCare Pharma's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(9587.325-130.264)/2290.366
=4.13

InnoCare Pharma's Quick Ratio for the quarter that ended in Jun. 2024 is calculated as

Quick Ratio (Q: Jun. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(8688.323-127.442)/2273.17
=3.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InnoCare Pharma  (HKSE:09969) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


InnoCare Pharma Quick Ratio Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCare Pharma Business Description

Traded in Other Exchanges
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
Executives
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
Cui Jisong
King Bridge Investments Limited 2101 Beneficial owner
Pang Kee Chan Hebert 2201 Interest of corporation controlled by you
Shi Yigong
Zhao Renbin
Sunny View Holdings Limited
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Hhlr Fund, L.p. 2101 Beneficial owner
Highbury Investment Pte Ltd 2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd. 2102 Investment manager
Tmf (cayman) Ltd. 2301 Trustee
Sunland Biomed Ltd 2101 Beneficial owner

InnoCare Pharma Headlines

No Headlines